N 6022

Drug Profile

N 6022

Alternative Names: N6022

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NitroMed
  • Developer Nivalis Therapeutics
  • Class Amides; Anti-inflammatories; Antiasthmatics; Carboxylic acids; Pyrroles; Small molecules
  • Mechanism of Action Alcohol dehydrogenase inhibitors; Glutathione-independent formaldehyde dehydrogenase inhibitors; Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute asthma; Asthma; Chronic obstructive pulmonary disease; Inflammatory bowel diseases
  • Discontinued Cystic fibrosis

Most Recent Events

  • 25 Jul 2017 Alpine Immune Sciences has merged with Nivalis Therapeutics forming Alpine Immune Sciences
  • 31 May 2014 N30 Pharmaceuticals completes a phase Ib trial in Cystic fibrosis in USA (NCT01746784)
  • 20 Mar 2013 Preclinical pharmacodynamics data from a mouse model of asthma released by N30 Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top